FT
ARQT icon

Fiduciary Trust’s Arcutis Biotherapeutics ARQT Stock Holding History

Fiduciary Trust’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$386K Buy
14,712
+4,092
+39% +$95.3K ﹤0.01% 674
2026
Q1 		$250K Hold
10,620
– – ﹤0.01% 790
2025
Q4 		$308K Sell
10,620
-5,536
-34% -$142K ﹤0.01% 706
2025
Q3 		$305K Hold
16,156
– – ﹤0.01% 704
2025
Q2 		$227K Hold
16,156
– – ﹤0.01% 770
2025
Q1 		$253K Buy
+16,156
New +$228K ﹤0.01% 712

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Fiduciary Trust's ARQT Position: Q2 2026 in Review

Fiduciary Trust increased its Arcutis Biotherapeutics (ARQT) stake by 39% in Q2 2026, buying an estimated $95.3K and bringing the position to 14,712 shares worth $386K. The position accounts for ﹤0.01% of the portfolio, ranked #674.

Fiduciary Trust first reported a position in ARQT in Q1 2025 and has held it in 6 quarters since. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Fiduciary Trust held 14,712 shares of Arcutis Biotherapeutics worth $386K as of Q2 2026.
  • Fiduciary Trust bought 4,092 Arcutis Biotherapeutics shares in Q2 2026, an estimated $95.3K.
  • Arcutis Biotherapeutics made up ﹤0.01% of Fiduciary Trust's portfolio in Q2 2026, its #674 holding.
  • Fiduciary Trust first reported a position in Arcutis Biotherapeutics in Q1 2025 and has held it in 6 quarters since.
  • 273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.